Literature DB >> 31012363

Quality of life among patients after cystoprostatectomy as the treatment for locally advanced prostate cancer with bladder invasion.

Peng Yuan1, Shen Wang1, Xifeng Sun1, Hua Xu1, Zhangqun Ye1, Zhiqiang Chen1.   

Abstract

PURPOSE: This study aimed to evaluate the changes of patients' quality of life (QoL) after cystoprostatectomy as a treatment for locally advanced prostate cancer (LAPC) with the bladder invasion and to determine risk factors for postoperative poor QoL.
MATERIALS AND METHODS: Between Jan 2012 and December 2015, 27 patients who received cystoprostatectomy for LAPC with the bladder invasion were retrospectively included. QoL was assessed with the functional assessment of cancer therapy-prostate (FACT-P) questionnaire scores. Determinants for postoperative poor QoL were investigated using univariate and multivariate regression analysis.
RESULTS: Three-year overall survival, biochemical progression-free survival, and clinical progress-free survival were 88.89%, 62.96% and 77.78%, respectively. Preoperative symptoms of hematuria, urinary frequency, and dysuria were well alleviated after cystoprostatectomy. Moreover, FACT-P questionnaire scores at 6 months and 1 year after cystoprostatectomy were significantly higher than preoperative scores. Univariate and multivariable analysis (p < .05) showed that postoperative complication was the independent risk factor for the loss of postoperative QoL.
CONCLUSIONS: Patients' QoL can be improved after cystoprostatectomy as the treatment for LAPC with the bladder invasion, which is associated with ameliorative urinary symptoms after the surgery. Besides, surgical complication is identified to be a risk factor for postoperative poor QoL.

Entities:  

Keywords:  Cystoprostatectomy; FACT-P questionnaire; bladder invasion; locally advanced prostate cancer; quality of life

Mesh:

Year:  2019        PMID: 31012363     DOI: 10.1080/13685538.2019.1604653

Source DB:  PubMed          Journal:  Aging Male        ISSN: 1368-5538            Impact factor:   5.892


  2 in total

1.  The auxiliary diagnostic value of prostate-specific antigen and α-methylacyl-CoA racemase in prostate cancer.

Authors:  Daijun Yang; Xiang Shi; Yu Lei; Xianrong Zhou; Qiuxiang Chen
Journal:  Oncol Lett       Date:  2020-05-21       Impact factor: 2.967

2.  Multimodal therapy including robot-assisted radical cystoprostatectomy for locally advanced prostate cancer with bladder and ureteral invasion: A case report.

Authors:  Masayoshi Okumi; Yuma Kujime; Soichi Matsumura; Hiroaki Kitakaze; Kosuke Nakano; Sachiko Hongo; Iwao Yoshioka; Shingo Takada
Journal:  IJU Case Rep       Date:  2022-06-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.